诺和诺德新疗法未展现出显著的阿尔茨海默病减缓效果_老虎社区_美港股上老虎

诺和诺德新疗法未展现出显著的阿尔茨海默病减缓效果

老虎资讯综合11-24

周一，诺和诺德盘前直线下挫，截至发稿大跌超12%。诺和诺德公布的Evoke III期临床试验并未显示出在统计学上显著减缓阿尔茨海默病进展的作用。

EVOKE实验

诺和诺德的EVOKE实验旨在测试和开发一种名为Amucantamab（也称为“点刺”或“刺突”）的新疗法，用于治疗阿尔兹海默病，特别是用于清除大脑中的淀粉样蛋白斑块。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

takahashi
·11-24
礼来有？
回复
1
举报
金虎玩股
·11-24
👀
回复
1
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1152104432?lang=zh_CN&edition=full","thumbnail":"https://community-static.tradeup.com/news/f08a53a8889b77ec7429556edaeae0b7","is_english":false,"pubTime":"2025-11-24 19:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152104432","market":"us","top_or_hot":-1,"title":"诺和诺德新疗法未展现出显著的阿尔茨海默病减缓效果","media":"老虎资讯综合","content":"<html><head></head><body><p>周一， <a href=\"https://laohu8.com/S/NVO\">诺和诺德</a> 盘前直线下挫，截至发稿大跌超12%。诺和诺德公布的Evoke III期临床试验并未显示出在统计学上显著减缓阿尔茨海默病进展的作用。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2e8a2685789ca2300a6fa0e151e63ded\" title=\"\" tg-width=\"1170\" tg-height=\"429\"/></p><p><strong>EVOKE实验</strong></p><p>诺和诺德的EVOKE实验旨在测试和开发一种名为Amucantamab（也称为“点刺”或“刺突”）的新疗法，用于治疗阿尔兹海默病，特别是用于清除大脑中的淀粉样蛋白斑块。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德新疗法未展现出显著的阿尔茨海默病减缓效果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德新疗法未展现出显著的阿尔茨海默病减缓效果\n</h2>\n\n<h4 class=\"meta\">\n\n2025-11-24 19:27 北京时间&nbsp;&nbsp;&nbsp;<strong>老虎资讯综合</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>周一， 诺和诺德 盘前直线下挫，截至发稿大跌超12%。诺和诺德公布的Evoke III期临床试验并未显示出在统计学上显著减缓阿尔茨海默病进展的作用。EVOKE实验诺和诺德的EVOKE实验旨在测试和开发一种名为Amucantamab（也称为“点刺”或“刺突”）的新疗法，用于治疗阿尔兹海默病，特别是用于清除大脑中的淀粉样蛋白斑块。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1152104432","we_media_id":"102","thumbnails":["https://community-static.tradeup.com/news/f08a53a8889b77ec7429556edaeae0b7"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152104432","pubTimestamp":1763983663,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"老虎资讯综合","introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"未显示出显著的阿尔茨海默病减缓效果。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"Novo Nordisk's new therapy does not show significant Alzheimer's disease alleviation effect","themeId":"c4dd3317d59b6ed3d7569f1d532c0719","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/9e018f67045496bef75af053b971e96b","symbols_score_info":{"NVO":2},"content_text":"周一， 诺和诺德 盘前直线下挫，截至发稿大跌超12%。诺和诺德公布的Evoke III期临床试验并未显示出在统计学上显著减缓阿尔茨海默病进展的作用。EVOKE实验诺和诺德的EVOKE实验旨在测试和开发一种名为Amucantamab（也称为“点刺”或“刺突”）的新疗法，用于治疗阿尔兹海默病，特别是用于清除大脑中的淀粉样蛋白斑块。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":503671456424712,"gmtCreate":1763989058994,"gmtModify":1763989061301,"author":{"id":"3576119814530073","authorId":"3576119814530073","name":"takahashi","avatar":"https://static.tigerbbs.com/3f12c7d8784688fa5f83836ec48f9e90","vip":1,"crmLevel":9,"crmLevelSwitch":0,"idStr":"3576119814530073","authorIdStr":"3576119814530073"},"htmlText":"礼来有？","listText":"礼来有？","text":"礼来有？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/503671456424712","repostId":1152104432,"repostType":2,"repost":{"id":"1152104432","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1763983663,"share":"https://www.laohu8.com/m/news/1152104432?lang=&edition=full","pubTime":"2025-11-24 19:27","market":"us","language":"zh","title":"诺和诺德新疗法未展现出显著的阿尔茨海默病减缓效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1152104432","media":"老虎资讯综合","summary":"未显示出显著的阿尔茨海默病减缓效果。","content":"<html><head></head><body><p>周一， <a href=\"https://laohu8.com/S/NVO\">诺和诺德</a> 盘前直线下挫，截至发稿大跌超12%。诺和诺德公布的Evoke III期临床试验并未显示出在统计学上显著减缓阿尔茨海默病进展的作用。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2e8a2685789ca2300a6fa0e151e63ded\" title=\"\" tg-width=\"1170\" tg-height=\"429\"/></p><p><strong>EVOKE实验</strong></p><p>诺和诺德的EVOKE实验旨在测试和开发一种名为Amucantamab（也称为“点刺”或“刺突”）的新疗法，用于治疗阿尔兹海默病，特别是用于清除大脑中的淀粉样蛋白斑块。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德新疗法未展现出显著的阿尔茨海默病减缓效果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德新疗法未展现出显著的阿尔茨海默病减缓效果\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-11-24 19:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>周一， <a href=\"https://laohu8.com/S/NVO\">诺和诺德</a> 盘前直线下挫，截至发稿大跌超12%。诺和诺德公布的Evoke III期临床试验并未显示出在统计学上显著减缓阿尔茨海默病进展的作用。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2e8a2685789ca2300a6fa0e151e63ded\" title=\"\" tg-width=\"1170\" tg-height=\"429\"/></p><p><strong>EVOKE实验</strong></p><p>诺和诺德的EVOKE实验旨在测试和开发一种名为Amucantamab（也称为“点刺”或“刺突”）的新疗法，用于治疗阿尔兹海默病，特别是用于清除大脑中的淀粉样蛋白斑块。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://community-static.tradeup.com/news/f08a53a8889b77ec7429556edaeae0b7","relate_stocks":{"NVO":"诺和诺德"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152104432","content_text":"周一， 诺和诺德 盘前直线下挫，截至发稿大跌超12%。诺和诺德公布的Evoke III期临床试验并未显示出在统计学上显著减缓阿尔茨海默病进展的作用。EVOKE实验诺和诺德的EVOKE实验旨在测试和开发一种名为Amucantamab（也称为“点刺”或“刺突”）的新疗法，用于治疗阿尔兹海默病，特别是用于清除大脑中的淀粉样蛋白斑块。","news_type":1,"symbols_score_info":{"NVO":2}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":503650320974512,"gmtCreate":1763984162287,"gmtModify":1763989350514,"author":{"id":"4188105060992060","authorId":"4188105060992060","name":"金虎玩股","avatar":"https://static.tigerbbs.com/a7034fabd6f05808492acc5802e834a6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4188105060992060","authorIdStr":"4188105060992060"},"htmlText":"👀","listText":"👀","text":"👀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/503650320974512","repostId":1152104432,"repostType":2,"repost":{"id":"1152104432","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1763983663,"share":"https://www.laohu8.com/m/news/1152104432?lang=&edition=full","pubTime":"2025-11-24 19:27","market":"us","language":"zh","title":"诺和诺德新疗法未展现出显著的阿尔茨海默病减缓效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1152104432","media":"老虎资讯综合","summary":"未显示出显著的阿尔茨海默病减缓效果。","content":"<html><head></head><body><p>周一， <a href=\"https://laohu8.com/S/NVO\">诺和诺德</a> 盘前直线下挫，截至发稿大跌超12%。诺和诺德公布的Evoke III期临床试验并未显示出在统计学上显著减缓阿尔茨海默病进展的作用。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2e8a2685789ca2300a6fa0e151e63ded\" title=\"\" tg-width=\"1170\" tg-height=\"429\"/></p><p><strong>EVOKE实验</strong></p><p>诺和诺德的EVOKE实验旨在测试和开发一种名为Amucantamab（也称为“点刺”或“刺突”）的新疗法，用于治疗阿尔兹海默病，特别是用于清除大脑中的淀粉样蛋白斑块。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德新疗法未展现出显著的阿尔茨海默病减缓效果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德新疗法未展现出显著的阿尔茨海默病减缓效果\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-11-24 19:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>周一， <a href=\"https://laohu8.com/S/NVO\">诺和诺德</a> 盘前直线下挫，截至发稿大跌超12%。诺和诺德公布的Evoke III期临床试验并未显示出在统计学上显著减缓阿尔茨海默病进展的作用。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2e8a2685789ca2300a6fa0e151e63ded\" title=\"\" tg-width=\"1170\" tg-height=\"429\"/></p><p><strong>EVOKE实验</strong></p><p>诺和诺德的EVOKE实验旨在测试和开发一种名为Amucantamab（也称为“点刺”或“刺突”）的新疗法，用于治疗阿尔兹海默病，特别是用于清除大脑中的淀粉样蛋白斑块。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://community-static.tradeup.com/news/f08a53a8889b77ec7429556edaeae0b7","relate_stocks":{"NVO":"诺和诺德"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152104432","content_text":"周一， 诺和诺德 盘前直线下挫，截至发稿大跌超12%。诺和诺德公布的Evoke III期临床试验并未显示出在统计学上显著减缓阿尔茨海默病进展的作用。EVOKE实验诺和诺德的EVOKE实验旨在测试和开发一种名为Amucantamab（也称为“点刺”或“刺突”）的新疗法，用于治疗阿尔兹海默病，特别是用于清除大脑中的淀粉样蛋白斑块。","news_type":1,"symbols_score_info":{"NVO":2}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":1,"commentSize":2,"repostSize":2,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}